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Abstract
Rapid diagnostic tests (RDTs) for malaria have improved the availability of parasite-based diagnosis throughout the malaria-endemic
world. Accurate malaria diagnosis is essential for malaria case management, surveillance, and elimination. RDTs are inexpensive, simple
to perform, and provide results in 15–20 min. Despite high sensitivity and speciﬁcity for Plasmodium falciparum infections, RDTs have
several limitations that may reduce their utility in low-transmission settings: they do not reliably detect low-density parasitaemia
(£200 parasites/lL), many are less sensitive for Plasmodium vivax infections, and their ability to detect Plasmodium ovale and Plasmodium
malariae is unknown. Therefore, in elimination settings, alternative tools with higher sensitivity for low-density infections (e.g. nucleic
acid-based tests) are required to complement ﬁeld diagnostics, and new highly sensitive and speciﬁc ﬁeld-appropriate tests must be
developed to ensure accurate diagnosis of symptomatic and asymptomatic carriers. As malaria transmission declines, the proportion of
low-density infections among symptomatic and asymptomatic persons is likely to increase, which may limit the utility of RDTs. Monitor-
ing malaria in elimination settings will probably depend on the use of more than one diagnostic tool in clinical-care and surveillance
activities, and the combination of tools utilized will need to be informed by regular monitoring of test performance through effective
quality assurance.
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Introduction
The diagnosis of malaria has evolved rapidly in the last
10 years, largely because of the introduction of rapid diag-
nostic tests (RDTs) for malaria. As malaria transmission
declines throughout the world, accurate diagnosis is becom-
ing increasingly important both for individual case manage-
ment and for disease surveillance. In early 2010, the WHO
recommended that all suspected malaria cases should be
conﬁrmed with a parasite-based diagnostic assay [1]. This
new policy stands in stark contrast to prior WHO recom-
mendations, which supported universal treatment of febrile
children <5 years of age in malaria-endemic areas, and
empirical treatment of older children and adults in areas
where laboratory testing was unavailable. Currently 78 (91%)
of the 86 countries where Plasmodium falciparum is endemic
have adopted policies to conﬁrm malaria with a laboratory
test prior to treatment in all age groups [2]. However,
despite the rapid change of policy, many countries are still
struggling to implement a comprehensive diagnostic pro-
gramme for malaria. In 2009, 21 (50%) of 42 reporting coun-
tries in the WHO Africa Region reported that fewer than
20% of suspected malaria cases were laboratory-conﬁrmed
[2]. Fortunately, the Africa Region is increasing the propor-
tion of laboratory-conﬁrmed cases, and this positive trend is
being noted in nearly all WHO Regions.
Prompt, reliable diagnosis is essential for the effective
management of malaria. Clinical signs and symptoms are not
speciﬁc for malaria infection, and result in overdiagnosis of
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malaria and inappropriate treatment of non-malarial illness
with antimalarial drugs [3–5]. Misdiagnosis of hospitalized
patients with non-malarial febrile illness can be associated
with higher mortality than malaria infection in malaria-ende-
mic countries [6,7], and inappropriate use of antimalarial
drugs contributes to the development of antimalarial drug
resistance [8,9]. Expansion of the diagnostic capacity for
malaria has the potential to reduce inappropriate use of anti-
malarial drugs. However, in many settings, providers neither
test patients meeting the suspected malaria case deﬁnition
nor adhere to test results when diagnosing and treating
malaria [10–15]. There are many potential reasons for poor
adherence to test results, including the lack of tests for
other diseases, poor understanding of the epidemiology of
febrile disease in malaria-endemic settings, patient expecta-
tions, unclear policies on managing negative results [16], low
conﬁdence in laboratory results, and the legacy of treatment
based on clinical symptoms. Despite these challenges, several
malaria-endemic countries have successfully introduced RDTs
at the most peripheral levels of the health system, in some
instances even down to the community health worker [17–
19]. The combination of early and accurate diagnosis by
RDT and early treatment with artemisinin-based combination
therapy by community health workers has also demonstrated
the ability to reduce malaria morbidity and mortality in low-
transmission settings [20,21].
Advantages and Limitations of RDTs
Malaria RDTs are immunochromatographic tests that detect
parasite antigens in whole blood samples. RDTs offer several
advantages over clinical diagnosis or microscopy. In ﬁeld tri-
als, they have demonstrated ‡90% sensitivity and speciﬁcity
for P. falciparum infection with ‡200 parasites/lL [22–24].
They are simple in comparison with other malaria diagnostic
tests, because they do not require electricity or expensive
equipment. They provide results in 15–20 min, and they are
relatively inexpensive, at $0.60–1.20 per test. RDTs are sim-
ple to use, and clinicians or community health workers can
be taught to perform them with a half day or full day of
didactic and practical training. Correct interpretation of
RDTs is less subjective than that of microscopy—the test
line is either present or absent. Currently available RDT
products detect one or more of three target antigens. Histi-
dine-rich protein 2 (HRP2)-detecting tests are highly sensi-
tive and speciﬁc for P. falciparum. Plasmodium lactate
dehydrogenase-based tests can be species-speciﬁc for P. falci-
parum or Plasmodium vivax or detect all malaria species (pan-
speciﬁc). A minority of commercially available RDT products
also use Plasmodium aldolase as a pan-species target antigen.
RDTs typically have a shelf-life of 18–24 months, allowing
sufﬁcient time for delivery, distribution, and use in most set-
tings. Because of their ease of use and accuracy, RDTs have
an increased capacity to provide malaria diagnosis in nearly
all healthcare settings, an essential component of accurate
disease surveillance in an elimination setting.
However, RDTs do have some disadvantages. RDTs, espe-
cially HRP2-based tests, are highly sensitive for P. falciparum
infections above 100–200 parasites/lL, but presently do not
reliably detect lower-density parasitaemia. Results for the
detection of P. vivax are more variable at densities of 100–
200 parasites/lL or even at higher parasite densities, depend-
ing on the target antigen and the product [25]. Of the 45
products tested in recent WHO/FIND/CDC evaluations,
only nine had panel detection scores of ‡90% when tested
against clinical samples of P. vivax at 200 parasites/lL [26].
Detection rates for Plasmodium ovale and Plasmodium malariae
were not included in the WHO/FIND/CDC product testing,
and there are limited data from ﬁeld trials, which do suggest
that there is considerable unreliability in detecting infections
with these two species. Quantiﬁcation of malaria parasita-
emia is an essential part of managing severe malaria and
monitoring treatment response, but is not possible with
RDTs that give qualitative results only. RDTs cannot distin-
guish current from recently treated infections, especially
those that detect HRP2, which may remain positive for sev-
eral weeks after treatment. Persistent positivity of RDTs
may be incorrectly interpreted by health workers as treat-
ment failure, reducing conﬁdence in antimalarial drug effec-
tiveness. There has also been considerable variation in the
manufacturing quality of RDTs. Some RDT products are con-
sistently poor performers, with considerable inter-lot vari-
ability, whereas others have only minor inter-lot variability
[26]. The monoclonal antibodies that are used to bind anti-
gen and produce a positive test result are also sensitive to a
combination of heat and humidity, especially those used in
Plasmodium lactate dehydrogenase-based tests, and may
degrade in the tropical conditions common to many malaria-
endemic countries when not protected by appropriate pack-
aging. There is also recent evidence that HRP2-based RDTs
may miss P. falciparum infections in regions where the hrp2
genes are deleted from a large proportion of the parasite
population, or at low parasitaemia densities, when there are
fewer repeated epitopes in the HRP2 product [27,28], but
the frequency of such deletions and lower repeat epitope
copy numbers remains poorly deﬁned in most settings.
Finally, quality control of RDTs in remote locations is chal-
lenging, because there are currently few available positive
controls or other tools for determining the reliability of
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RDTs in use in ﬁeld locations. Therefore, quality control is
frequently limited to supervisory visits or review of blood
smears at locations away from the point of use. Despite
these challenges, RDTs remain a useful and widely deployed
diagnostic tool for malaria surveillance and control.
Alternatives for Malaria Diagnosis
Other methods of malaria diagnosis require signiﬁcantly
greater investments in equipment, reagents, and training. The
historical reference standard for malaria diagnosis is light
microscopy. It is highly sensitive and speciﬁc when used by a
highly competent microscopist working with an optimally
functioning microscope and good reagents, and can reliably
detect as few as 10 parasites/lL. However, because micro-
scopy requires extensive training, quality materials, and sev-
eral years of experience to attain and maintain proﬁciency,
routine diagnosis by microscopy is of variable quality, and
lower-density infections are frequently not identiﬁed. Nucleic
acid-based tests (NATs) have consistently demonstrated
superiority to RDTs and microscopy in detecting infections
at levels below the detection limits of a competent micros-
copist [29–34]. As countries progress towards malaria elimi-
nation, the need to detect submicroscopic infections is
becoming increasingly important, as reservoirs of infected
persons may sustain transmission even without this manifest-
ing in clinical illness. Therefore, it may be necessary to incor-
porate more sensitive NATs into elimination programmes.
NATs differ in their sensitivity, ease of use, and other
requirements, such as DNA targets, primers and probes, and
instrumentation. The most commonly used NATs for para-
site detection are nested-PCR ampliﬁcation and quantitative
nucleic acid sequence-based ampliﬁcation PCR. Other NATs,
such as loop-mediated isothermal ampliﬁcation [35–38] and
ﬂuorescent microbead technology [32,39,40], have also been
described. Increased sensitivity is achieved with these tests
by repeated ampliﬁcation of an initially low level of parasite
genetic material and subsequent detection by speciﬁc ﬂuores-
cent tags. In addition, primers and probes can be designed
for different Plasmodium species and, possibly, variants within
a species. Because the critical steps of ampliﬁcation and
detection are automated, test results are less subjective than
those of microscopy and RDTs. When appropriately cali-
brated and targeted, some real-time NATs have the addi-
tional advantage of parasite quantiﬁcation.
The currently available NATs are not suitable for routine
malaria diagnosis, because they require expensive equipment
and expensive reagents that require refrigeration, along with
highly qualiﬁed technicians. They are best suited for special-
ized laboratories that rarely exist in clinical-care settings in
most malaria-endemic countries. However, these drawbacks
do not necessarily preclude their use in elimination settings
as adjuncts to microscopy and RDTs. Indeed, their amenabil-
ity to high throughput means that samples from multiple loca-
tions can be collected and sent to a central laboratory for
analyses, which is more cost-effective. Further cost savings
can be realized by DNA sample pooling [41,42] in elimination
settings, where most samples are expected to be parasite-
negative. Expected innovations, such as making NATs less
costly, easier to perform, and ﬁeld ready, will allow their use
in a variety of elimination settings and vastly improve the
quality of surveillance in low-transmission settings.
Another surveillance tool that may be useful in elimination
and near-elimination settings is malaria serology. Population-
level antibody responses to certain Plasmodium parasite anti-
gens can be used to determine transmission trends over a
period of months to years [43–45]. The choice of the spe-
ciﬁc antigen targeted for serological monitoring will depend
on characteristics such as immunogenicity and seroconver-
sion rates, persistence of the speciﬁc antibody (decay rate),
and limited variation in the target antigen. Serological testing
could provide useful population-level data with which to
measure progress in control and elimination programmes,
but is unsuitable for individual case management in endemic
settings.
The diagnostic tools mentioned above will probably be
deployed in combination in elimination settings. The Malaria
Eradication Research Agenda Consultative Group on Diagno-
sis and Diagnostics recommended that, as countries shift
from control to eradication, the emphasis may shift from
light microscopy and RDTs to greater reliance on appropri-
ate NATs and serology [46]. Speciﬁc programme require-
ments and malaria transmission dynamics will determine
which test combinations are deployed for individual clinical
diagnosis at each level of the health system for passive case
detection, for active case detection, and for population-level
surveillance. Identiﬁcation and treatment of individuals with
asymptomatic malaria infections is critical to the success of
elimination programmes. Therefore, the use of RDTs for
case management and surveillance in elimination settings
requires an understanding of the limitations of these tests, in
order to adjust diagnostic strategies when necessary and also
to put test results in the appropriate perspective. Until tests
with greater sensitivity are able to be performed in periph-
eral health centres and/or by community health workers,
RDTs remain the best option for laboratory-conﬁrmed diag-
nosis of malaria in remote locations. However, population-
level surveillance will probably require more sensitive tests
to estimate the true burden of malaria infection.
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Parasite Density and RDTs in Surveillance
Making informed decisions about the utility of RDTs in elimi-
nation settings requires knowledge of the proportion of low-
density infections in symptomatic and asymptomatic persons.
The proportion of such infections is likely to be inﬂuenced
by a variety of factors, including disease endemicity, parasite
species and strain virulence, host factors such as age, race,
prior malaria exposure, haemoglobinopathies, and others
[47–51]. Recent studies using PCR in low-transmission set-
tings have demonstrated a high proportion of low-density
parasitaemias that were not detected by microscopy or
RDT, and revealed that a high proportion of infected individ-
uals were asymptomatic [29,52,53]. Traditionally, it is to be
expected that many asymptomatic infections will be found in
areas of high malaria prevalence, because of acquired immu-
nity resulting from repeated infections. Conversely, because
areas of low or sporadic malaria transmission provide less
malaria exposure, the convention is to expect to ﬁnd few
asymptomatic infections. However, in areas where malaria
transmission has decreased rapidly over a relatively short
period of time, there may be different effects of waning
immunity on the proportion of asymptomatic infections than
in areas where low or sporadic malaria transmission has
been sustained for decades. These new data suggest the
potential limited utility of RDTs for monitoring disease or
parasite prevalence in some elimination settings. However,
parasite densities associated with asymptomatic infections
are not static, and may need to be periodically monitored to
determine whether RDT use remains appropriate.
Malaria Indicator Surveys (MISs) may provide a useful
means of monitoring low-density infection prevalence among
symptomatic and asymptomatic children. The proportion of
low-density P. falciparum infections (<200 parasites/lL) in
asymptomatic and symptomatic children was highly variable
in Kenya, Mozambique, Senegal and Zambia MISs, ranging
from 2.6% to 29.7% of children surveyed with positive blood
smears (Fig. 1). Despite the variability in the proportion of
low-density infections, the overall sensitivity of RDTs
remained relatively high in all four surveys, ranging from
80.5% to 97.7% (Table 1). The sensitivity for low-density
infections (<200 parasites/lL) was less consistent, ranging
from 71.7% to 100% (data not shown). The speciﬁcity
remained over 90% in all surveys except for that in Moza-
mbque (74.6%). Higher parasite prevalence and recently
treated infections may have led to a higher proportion of
false-positive RDT results because of ongoing HRP2 circula-
tion reducing speciﬁcity in Mozambique. The parasite preva-
lence measured by RDTs was consistently higher than that
measured by microscopy in all four surveys, which may
represent continued HRP2 antigenaemia following treatment,
submicroscopic infection, or human error in labelling, inter-
preting or recording test results. The Roll Back Malaria
Monitoring and Evaluation Reference Group is considering
recommending the use of RDTs alone for future MISs, which
FIG. 1. Proportion of positive blood smears with Plasmodium falciparum parasite density <100, <200 and <500 parasites/lL in symptomatic and
asymptomatic children 6–59 months of age surveyed during Malaria Indicator Surveys, 2007–2009.
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could limit the ability to monitor parasite density, and gamet-
ocytaemia, and will have unknown effects on the monitoring
of P. ovale and P. malariae infections.
Studies of the pyrogenic threshold for P. falciparum malaria
in immunonaı¨ve individuals have demonstrated a wide spec-
trum of parasitaemias at fever onset, ranging from 10 to
200 000 parasites/lL [54]. Data from several malaria-ende-
mic countries indicate that the proportion of low-density
(<200 parasites/lL) infections in symptomatic persons is
higher in low-transmission than in high-transmission areas,
and also higher in P. vivax than in P. falciparum infections [55].
This suggests that a larger proportion of symptomatic cases
may be missed in low-transmission (i.e. elimination) settings
and for P. vivax infections if RDTs are the sole means of par-
asitological conﬁrmation. However, these studies were con-
ducted with conﬁrmation by microscopy alone, and the true
burden of submicroscopic infection may be much higher
when determined by PCR [56]. Irrespective of the parasite
density, all malaria infections, if not identiﬁed and treated,
represent parasite reservoirs with the potential to infect
mosquitoes [31,34,57]. Active case detection will be an
essential component of any elimination plan. Malaria control
programmes will also need to actively monitor the sensitivity
of RDTs and microscopy in detecting low-density parasita-
emia in symptomatic patients presenting to health facilities
and in population-based surveys to capture asymptomatic
infections with more sensitive NATs. The development of
more sensitive RDTs would be ideal, but there will be limits
to detection with immunochromatographic tests without an
ampliﬁcation step to increase parasite detection.
Malaria Surveillance in Elimination Settings
Nearly all malaria-endemic areas experience some degree of
seasonality in malaria transmission associated with periods of
increased rainfall. The proportion of fevers attributable to
malaria illness will rise in the high-transmission season and
fall in the low-transmission season. Likewise, the proportion
of fevers attributed to malaria will decrease as malaria elimi-
nation progresses [58], while other febrile diseases may
remain relatively stable in the population and appear to be
relatively more important. A reduction in the proportion of
fever cases positive for malaria may have consequences for
the use of RDTs and malaria case management. First, there
could be an erroneous perception by health workers that
negative test results are frequently false-negative results, and
this may reduce conﬁdence in the tests [59]. Second, a high
prevalence of non-malarial fevers may discourage testing for
malaria, resulting in missed malaria cases. Therefore, the use
of RDTs in elimination settings may require substantial
efforts to maintain regular testing and quality case manage-
ment. However, doing this means that resources will be chan-
nelled into testing for a very low-prevalence disease that
could be used for managing non-malaria fevers. Without the
ability to test for and diagnose other febrile illnesses, health
practitioners may revert to treating all fevers as malaria or
to injudiciously prescribing antibiotics for a broader range
of symptoms associated with fever. Dissatisfaction with a
‘not malaria’ diagnosis may arise as patients become more
informed health consumers. Improving diagnostic resources
and training for other causes of severe and non-severe febrile
illness will be an essential component of malaria elimination,
to encourage accurate testing and reporting of malaria cases.
High-quality malaria surveillance through rigorous testing of
symptomatic persons presenting to health facilities will help to
target other malaria control interventions in an elimination
setting. Early identiﬁcation of localized areas of high malaria
activity will allow targeted action to eliminate pockets of local
transmission, and may serve as a useful intervention tool to
reduce the further spread of malaria beyond the identiﬁed
zone. Quality malaria surveillance, including active case detec-
tion in travellers from malaria-endemic areas, will also be an
essential component of sustaining malaria elimination for
TABLE 1. Microscopy and rapid diagnostic test results from Malaria Indicator Surveys that collected the results of both
malaria tests, 2007–2009
Kenya 2007 Mozambique 2007 Senegal 2008–2009 Zambia 2008
Number with blood smear results 4598 3238 4139 3656
Malaria parasite prevalence by microscopy (%)a 3.6 31.7 6.3 9.7
RDT product ICT Malaria Pf
(ICT Diagnostics)
ICT Malaria Pf
(ICT Diagnostics)
Paracheck Pf
(Orchid Biomedical)
ICT Malaria Pf
(ICT Diagnostics)
Number with RDT results (positive/negative) 5117 3876 4032 3652
Malaria prevalence by RDT (%)a 8.1 43.8 12.0 16.3
Number with RDT and BS results 4582 2438 3960 3652
RDT sensitivity (%)b 94.0 87.0 80.5 97.7
RDT speciﬁcity (%)b 95.6 74.6 92.8 92.5
BS, blood smear; RDT, rapid diagnostic test.
aPrevalence estimates not weight-adjusted.
bMicroscopy considered to be the reference standard.
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countries that share borders with malaria-endemic nations
and those with frequent importation of malaria from travel-
lers. The infrastructure developed to improve malaria diagno-
sis during elimination may also be utilized to expand the
diagnostic capacity for other diseases, including tuberculosis
and human immunodeﬁciency virus disease: an individual
trained to perform malaria microscopy can be easily trained
to perform tuberculosis microscopy, and those trained to per-
form malaria RDTs would probably be capable of performing
human immunodeﬁciency virus rapid testing as well. Epidemio-
logical data regarding outcomes of non-malarial febrile disease
will also be useful to assist clinicians in determining the best
course of treatment for non-malarial febrile illness and to
reduce overprescription of antimalarial drugs and antibiotics.
Hypnozoites and Elimination of P. vivax and
P. ovale
Elimination of P. vivax and P. ovale malaria will be further com-
plicated by the presence of liver hypnozoites and the inability
of current tests to detect them. Plasmodium hypnozoites are
not eliminated by most antimalarial drug combinations, and
frequently cause relapse in patients who are not treated with
8-aminoquinoline drugs (primaquine, tafenoquine, and pamaq-
uine). Incorrect speciation or failure to identify mixed infec-
tions with P. vivax or P. ovale may result in continued
transmission of malaria from asymptomatic carriage of hypn-
ozoites that later mature and produce blood-stage infections.
Treatment with primaquine and other drugs in this class can
produce severe haemolytic anaemia in persons with glucose-
6-phosphate dehydrogenase (G6PD) deﬁciency, an inherited
enzymatic defect that is common in much of the malaria-
endemic world [60]. The currently available rapid G6PD
screening tests are relatively expensive and have not been
widely implemented. Identiﬁcation of alternative drugs for
eliminating hypnozoites or more affordable, rapid tests for
G6PD deﬁciency will be an essential component in safely elim-
inating P. vivax and P. ovale in malaria-endemic areas.
Conclusion
The currently available RDTs are useful tests for expanding
the availability of malaria diagnosis in a variety of ﬁeld set-
tings. They are highly sensitive for P. falciparum infections
with parasite densities of ‡200 parasites/lL, and a few prod-
ucts achieve similarly high sensitivity for P. vivax infections.
However, there is increasing evidence that low-density and
microscopically subpatent infections may be more common
than previously recognized in near-elimination settings.
Therefore, unless RDTs are able to improve sensitivity mea-
sures at low densities of parasitaemia without sacriﬁcing
speciﬁcity, newer diagnostic tools will be required for malaria
elimination. An ideal diagnostic test for malaria would have
high sensitivity and speciﬁcity at any density of parasitaemia,
be portable, and be easily and accurately used in ﬁeld set-
tings. In addition, the characteristics of an ideal test are likely
to differ for programmes at differing stages along the road
from malaria control to pre-elimination and elimination [46].
NATs already achieve high sensitivity, but are not currently
portable or simple enough for widespread use. Future
research and development in malaria diagnostics should
emphasize: highly sensitive detection of low-density infec-
tions; detection of liver-stage and sexual-stage parasites; mul-
tiplex systems to detect malaria and non-malarial causes of
illness or severity markers; and detection of G6PD deﬁciency
and other factors that may help to guide treatment. Monitor-
ing malaria in elimination settings will probably depend on
the use of more than one diagnostic tool in clinical-care and
surveillance activities, and the combination of tools utilized
will need to be informed by regular monitoring of test per-
formance through effective quality assurance. Investments in
improving malaria surveillance may seem costly, but will
probably be beneﬁcial in improving the diagnosis of other
diseases and preventing the re-introduction of malaria.
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